Tenderwize
Back to tender search

Framework agreement for CAR-T cell therapy active ingredients

Azienda ULSS n. 8 Berica·Vicenza, Italy·EUR 19.4M·Expired · Jul 06, 2026·Open·Supplies·Framework
High valueStructured notice only
Original notice title

Italy – Antineoplastic and immunomodulating agents – GARA EUROPEA A PROCEDURA APERTA PER LA FORNITURA, IN ACCORDO QUADRO MULTIFORNITORE, DI PRINCIPI ATTIVI PER TERAPIE CON CELLULE CAR-T DESTINATE A PAZIENTI IN CARICO ALL’AZIENDA ULSS N. 8 BERICA

30/100

Opportunity Score

Needs reviewMedium complexity
SuppliesFrameworkExpired
Why this score?

Opportunity

30 / 100

Complexity

60 / 100

Risk factors

The tender notice (XML) indicates the procedure is suspended due to a complaint (reclamo). Potential outcomes: cancella...

EU funding flag differs between structured data (EU-funded) and XML (no-eu-funds). Also, submission deadline time incon...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • EUR 19.4M estimated value
  • Framework procurement
  • Supplies contract
  • 3 lots
  • Duration 12 MONTH
  • Supply of active principles (pharmaceutical substances) for CAR-T cell therapies.
  • The products are intended for specific lymphoma indications: DLBCL (2nd and 3rd line), PMBCL (3rd line), and follicular lymphoma (4th line).
Show full summary

This is an open procedure tender for a multi-supplier framework agreement for the supply of active principles for CAR-T cell therapies, intended for patients under the care of Azienda ULSS n. 8 Berica (Italy). The tender is divided into three lots covering specific lymphoma therapies. The procedure is currently suspended due to a complaint (reclamo) as per the XML notice. The estimated total value across lots is €19,401,945. Award is based solely on price. Submission deadline is 2026-07-06 (10:00 or 12:00 – inconsistency noted). Important documents (e.g., ESPD) are required. EU funding status is inconsistent between structured data (EU-funded) and XML notice (no EU funds). The notice is in Italian only.

Risks

The tender notice (XML) indicates the procedure is suspended due to a complaint (reclamo). Potential outcomes: cancella...

EU funding flag differs between structured data (EU-funded) and XML (no-eu-funds). Also, submission deadline time incon...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Certifications

  • All communications and submissions must be electronic via Sintel or certified email (PEC) for Italian operators, or qualified electronic registered delivery service for...

Administrative

  • Registration on the Sintel e-procurement platform (ARIA SPA) is mandatory.
  • Tender must be accompanied by the European Single Procurement Document (ESPD) or equivalent.

Requirements may be incomplete.

Award Criteria

Lot 1

Award criterion: price only (lowest price).

Lot 2

Award criterion: price only (lowest price).

Lot 3

Award criterion: price only (lowest price).

Buyer

Location

Vicenza, ITA

Buyer profile

Open profile

Identifier

02441500242

Activity

Health

Lots (3)

LOT-0001

LOTTO 1 - Therapy for adult patients with DLBCL Lymphoma - 2nd Line and Therapy for adult patients with PMBCL Lymphoma - 3rd Line

Supply of active principles for CAR-T therapy for adult patients with DLBCL (2nd line) and PMBCL (3rd line). Framework agreement with a maximum value of €15,936,345, including a 12-month initial period and an optional 12-month renewal.

SuppliesFrameworkEU fundedElectronic submission

EUR 19.4M

Estimated value

Duration

12 MONTH

Category

Antineoplastic and immunomodulating agents

Award Criteria

Price

Deadline

Expired Jul 06, 2026

LOT-0002

LOTTO 2 - Therapy for adult patients with DLBCL Lymphoma - 3rd Line

Supply of active principles for CAR-T therapy for adult patients with DLBCL (3rd line). Framework agreement with a maximum value of €1,732,800, including a 12-month initial period and an optional 12-month renewal.

SuppliesFrameworkEU fundedElectronic submission

EUR 19.4M

Estimated value

Duration

12 MONTH

Category

Antineoplastic and immunomodulating agents

Award Criteria

Price

Deadline

Expired Jul 06, 2026

LOT-0003

LOTTO 3 - Therapy for adult patients with Follicular Lymphoma (FL) - 4th Line

Supply of active principles for CAR-T therapy for adult patients with follicular lymphoma (4th line). Framework agreement with a maximum value of €1,732,800, including a 12-month initial period and an optional 12-month renewal.

SuppliesFrameworkEU fundedElectronic submission

EUR 19.4M

Estimated value

Duration

12 MONTH

Category

Antineoplastic and immunomodulating agents

Award Criteria

Price

Deadline

Expired Jul 06, 2026

Procurement Details

Publication date
02 Jul 2026
Languages
Italian

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
456933-2026

Documents (2)

Similar tenders